These findings indicate more research is required to elucidate the effects of Aβ1-42 on KCC2 and NKCC1 expression in the human AD brain to explore if targeting CCCs might offer a therapeutic approach for AD, as we demonstrate altered CCC expression may be a contributing factor to the E/I imbalance in AD. The gene discussed is SLC12A2; the disease is Alzheimer disease.